# Perio Therapia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/perio-therapia

- Industry: Biotechnology
- Headquarters: Osaka, Japan
- Website: www.periotherapia.co.jp
- Total disclosed funding: $12M
- Latest round: Series D (Jun 2, 2026)
- Investors on record: 5

## About

Based in Japan, Periotherapia Co., Ltd., d.b.a. Perio Therapia, is engaged in developing pathological periostin-targeting antibody therapeutics, related diagnostic technologies, and drug discovery research for conditions including cancer and inflammatory diseases. Periotherapia Co., Ltd., d.b.a. Perio Therapia, focuses on therapeutics for challenging diseases and was founded in 2017 in Suita-shi, Japan. The company's CEO is TOCHIHARA Yosuke. In June 2026, Perio Therapia raised JPY 1.6 billion in Series D funding, venture debt, and grant funding from Mitsubishi UFJ Capital, Techno Science, the Japan Agency for Medical Research and Development, and unspecified financial institutions. Perio Therapia specializes in developing innovative therapeutics for hard-to-treat diseases, particularly with drug candidates targeting pathological periostin. Their primary offerings include neutralizing antibodies aimed at treating triple-negative breast cancer (TNBC) and other metastatic HER2-negative breast cancers. The company serves research institutions and healthcare providers primarily in Japan, while also preparing to enter international markets. Collaborations with prominent academic institutions like Osaka University enhance their product development, ensuring alignment with the latest scientific advancements. Perio Therapia generates revenue through partnerships and collaborations with academic institutions and pharmaceutical companies, focusing on the development and commercialization of their proprietary therapies. Revenue streams include funding from partners for clinical trials and product development, along with potential earnings from licensing agreements and milestone payments related to their therapeutic advancements. Specifically, their neutralizing antibodies targeting pathological periostin are anticipated to attract significant interest in both clinical and commercial spheres after reaching advanced stages of development. Perio Therapia will use the June 2026 funding to support ongoing and planned clinical trials, expand its pipeline, strengthen its organizational structure, and improve its financial stability.

## Funding rounds

- Series D, Jun 2, 2026 — Mitsubishi UFJ Capital, Techno Science
- Series D, Jun 27, 2024, $2.5M — Mitsubishi UFJ Capital, Osaka University Venture Capital, Chishima Real Estate Co., Ltd., Eisai, Techno Science
- Series C, Mar 8, 2022, $3.5M — Mitsubishi UFJ Capital, Osaka University Venture Capital
- Series B, Sep 30, 2020, $3.5M — Mitsubishi UFJ Capital, Osaka University Venture Capital
- Series A, Apr 5, 2019, $2.2M — Osaka University Venture Capital

## Investors

- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series A, Series B, Series C, Series D
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series B, Series C, Series D
- Chishima Real Estate Co., Ltd. — Series D
- Eisai — Series D
- Techno Science — Series D